|

CD20/CD22 dual Targeted CAR T-cells Clinical Trials

1 actively recruiting trial

Also known as: CD20/CD22 dual Targeted CAR T-cells injection

Pipeline

Early 1: 1

Top Sponsors

  • He Huang1

Indications

  • Lymphoid Hematological Malignancies1
  • Relapsed and Refractory1
  • Cancer1

Other1 trial

A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies
Early 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.